Weekly Vinorelbine versus Docetaxel for Metastatic Breast Cancer after Failing Anthracycline Treatment
| Autor: | Manfred Braun, Carl Richard Meier, Holger Deertz, Hans Jochen Illiger, Hueseyin Taylan Oeney, Susanne Rotermund, Martin Steder, Jan Janssen, Burkhard Deuss, Thomas Küchler |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty Lung Neoplasms Anthracycline Bone Neoplasms Breast Neoplasms Docetaxel Vinblastine Vinorelbine Quality of life Internal medicine Humans Medicine Anthracyclines Treatment Failure Aged business.industry Liver Neoplasms Hematology General Medicine Middle Aged medicine.disease Metastatic breast cancer Treatment Outcome Lymphatic Metastasis Female Taxoids business medicine.drug |
| Zdroj: | Onkologie. 31:447-453 |
| ISSN: | 1423-0240 0378-584X |
| Popis: | Vinorelbine and docetaxel are active in anthracycline-pretreated, metastatic breast cancer. We compared their efficacy.Patients were randomized to receive weekly vinorelbine (VIN) or weekly docetaxel (DOC), 6 weekly doses per 8-week cycle, with optional crossover (X-DOC vs. X-VIN. The primary end point was time to progression (TTP) on initial treatment. Remission induction, survival, and quality of life were secondary end points.Among 122 poor risk patients, a non-significant trend for better TTP was seen for DOC, both on initial and on crossover treatment. Responses were seen on either treatment, but progression was more common with VIN than with DOC, while more patients had a response with X-DOC than with X-VIN. Survival was identical in those receiving only the initial VIN vs. DOC and in the subgroups receiving crossover treatments. Grade 3-4 toxicity, especially hematological toxicity resulting in treatment delay, was more common with VIN. Non-graded toxicity contributed to abandoning DOC. Quality of life scores reflected worse results in patients crossing treatment arms, in either direction.DOC showed marginally better activity but did not improve TTP or other endpoints over VIN in this poor risk population. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|